FUJISAWA, Japan & BOSTON--(BUSINESS WIRE)--Jun 23, 2025-- Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The two companies have built a strong relationship through prior collaborations. Axcelead DDP provided high-quality in vivo pharmacological evaluations of proprietary compounds developed by Superluminal using its unique predict-design-test architecture.